SHR-A1811
SHR-A1811 is a pharmaceutical drug with 45 clinical trials. Currently 25 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 2 completed trials
Phase Distribution
Phase Distribution
10
Early Stage
25
Mid Stage
9
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
100.0%
2 of 2 finished
0.0%
0 ended early
25
trials recruiting
45
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Exploratory Study of SHR-A1811 Via Different Administration Routes in Patients
A Study of SHR-A1811 in Subjects With Ovarian Cancer
Neoadjuvant SHR-A1811 Combined With Pertuzumab in HER2-Positive Breast Cancer: An Exploratory Clinical Study.
Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer
A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular Typing
Clinical Trials (45)
Exploratory Study of SHR-A1811 Via Different Administration Routes in Patients
A Study of SHR-A1811 in Subjects With Ovarian Cancer
Neoadjuvant SHR-A1811 Combined With Pertuzumab in HER2-Positive Breast Cancer: An Exploratory Clinical Study.
Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer
A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular Typing
Study of SHR-A1811 in HER2-expression Advanced Breast Cancer With Brain Metastases
Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast Cancer
Study of Multi-mode Thermal Therapy Combined With Immunotherapy In Patients With HER2-negative Breast Cancer With Liver Metastases
SHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized Study
A Phase 1 Study of SHR-A1811 in Patients With Selected HER2 Expressing Tumors
Famitinib Combined With SHR-A1811, Versus SHR-A1811 for CDK4/6 Inhibitors-resistent Advanced HR+/HER2- Breast Cancer With SNF4 Subtype
Clinical Study of SHR-A1811 Combined With Pertuzumab as Second-Line Therapy in Patients With HER2-Altered Advanced NSCLC
Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast Cancer
A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations
Chemotherapy With or Without Adebrelimab and T-DXh as Neoadjuvant Therapy for HR+/HER2 Low Early Stage Breast Cancer
Trastuzumab Rezetecan in Advanced Solid Tumors Refractory to Standard Therapies
Clinical Study of SHR-A1811 With or Without Letrozole in Neoadjuvant Therapy for Early-Stage HR-Positive, HER2-Low Breast Cancer
Reverse Triple Negative Immune Resistant Breast Cancer
A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer
A Two-cohort Study of SHR-A1811 in the Treatment of HER2-positive Breast Cancer With Brain Metastases
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 45